Northern Biologics has reached an agreement for the acquisition of the company’s lead asset, MSC-1, by an AstraZeneca subsidiary. MSC-1 is an anti-LIF antibody that has completed Phase 1a clinical studies for the treatment of solid tumors. Deal terms are undisclosed. Metrix Partners has been collaborating with Mosaic Biomedicals, an affiliate of Northern Biologics, since the company’s early stage.
MSC-1 was Northern’s sole remaining asset following the May acquisition of preclinical assets by Boehringer Ingelheim.
“This transaction with AstraZeneca can both accelerate and expand the development of MSC-1,” said Philip Vickers, Ph.D., President and CEO of Northern Biologics. “I am pleased that in AstraZeneca we have found a great company to further develop this exciting antibody while also providing a return to our investors.”
Read the press release here